Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;5(4):569-81.
doi: 10.15171/apb.2015.077. Epub 2015 Nov 30.

Enhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets

Soad Ali Yehia  1 , Mohamed Shafik El-Ridi  2 , Mina Ibrahim Tadros  1 , Nolwa Gamal El-Sherif  3
Affiliations

Enhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets

Soad Ali Yehia et al. Adv Pharm Bull. 2015 Nov.

Abstract

Purpose: The current work aimed to develop promising Fexofenadine hydrochloride (FXD) liquisolid tablets able to increase its oral bioavailability and shorten time to reach maximum plasma concentrations (Tmax).

Methods: Eighteen liquisolid powders were developed based on 3 variables; (i) vehicle type [Propylene glycol (PG) or Cremophor(®) EL (CR)], (ii) carrier [Avicel(®) PH102] to coat [Aerosil(®) 200] ratio (15, 20, 25) and (iii) FXD concentration in vehicle (30, 35, 40 %, w/w). Pre-compression studies involved identification of physicochemical interactions and FXD crystallinity (FT-IR, DSC, XRD), topographic visualization (SEM) and estimation of flow properties (angle of repose, Carr's index, Hausner's ratio). CR-based liquisolid powders were compressed as liquisolid tablets (LST 9 - 18) and evaluated for weight-variation, drug-content, friability-percentage, disintegration-time and drug-release. The pharmacokinetics of LST-18 was evaluated in healthy volunteers relative to Allegra(®) tablets.

Results: Pre-compression studies confirmed FXD dispersion in vehicles, conversion to amorphous form and formation of liquisolid powders. CR-based liquisolid powders showed acceptable-to-good flow properties suitable for compaction. CR-based LSTs had appropriate physicochemical properties and short disintegration times. Release profile of LST-18 showed a complete drug release within 5 min.

Conclusion: LST-18 succeeded in increasing oral FXD bioavailability by 62% and reducing Tmax to 2.16 h.

Keywords: Cremophor® EL; Fexofenadine hydrochloride; Liquisolid tablets; Oral bioavailability; Pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5
Figure 6
Figure 6
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zu Y, Li N, Zhao X, Li Y, Ge Y, Wang W. et al. In vitro dissolution enhancement of micronized l-nimodipine by antisolvent re-crystallization from its crystal form h. Int J Pharm. 2014;464(1-2):1–9. doi: 10.1016/j.ijpharm.2014.01.020. - DOI - PubMed
    1. Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: Stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci. 2011;100(8):3365–73. doi: 10.1002/jps.22587. - DOI - PubMed
    1. Liu QY, Zhang ZH, Jin X, Jiang YR, Jia XB. Enhanced dissolution and oral bioavailability of tanshinone iia base by solid dispersion system with low-molecular-weight chitosan. J Pharm Pharmacol. 2013;65(6):839–46. doi: 10.1111/jphp.12047. - DOI - PubMed
    1. Cho YD, Park YJ. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate. Arch Pharm Res. 2014;37(2):193–203. doi: 10.1007/s12272-013-0169-4. - DOI - PubMed
    1. Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Mullertz A. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster tmax after oral dosing to rats. Eur J Pharm Biopharm. 2013;85(3 Pt B):942–51. doi: 10.1016/j.ejpb.2013.09.002. - DOI - PubMed

LinkOut - more resources